Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
RegulatoryapprovedUbesloEvlarcoPositive
AI Analysis
Summary
Menarini Group and NewAmsterdam Pharma received European Commission approval for Ubeslo and Evlarco, marking the first global regulatory approval of the first-in-class obicetrapib. The approvals are supported by Phase 3 trials (BROADWAY, BROOKLYN, TANDEM) demonstrating significant LDL-C reductions with favorable tolerability.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination). First-in-class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile.
Importance:9/10
Sentiment:
0.95
regulatory approvalEuropean Commissionfirst-in-classobicetrapibLDL-C reductionPhase 3 datafixed-dose combination
Related Companies
Read the original article
Published by PR Newswire Biotech on September 21, 2026 2:57 PM